GITNUX MARKETDATA REPORT 2024

Statistics About The Most Promising Glioblastoma Trials

The most promising glioblastoma trials are showing a statistically significant increase in progression-free survival rates compared to standard treatments.

Last Updated: June 23, 2024

Written & Summarized by: Jannik Lindner

How we write

In this post, we will explore the latest promising trials and treatments for Glioblastoma, a challenging form of brain cancer. From Optune to Pembrolizumab, Tumor Treating Fields to Bevacizumab, we’ll delve into the statistics and findings that show potential advancements in the field of Glioblastoma treatment and survival rates.

Statistic 1

"As reported in July 2021, the median survival rate for Glioblastoma patients in Optune clinical trials is 21 months."

Statistic 2

"According to a clinical trial, the use of Pembrolizumab showed around a 28% response rate in patients with Glioblastoma."

Statistic 3

"In a study of the drug Tumor Treating Fields (TTF), the 5-year survival rate was 13%, compared to a 5% rate using traditional treatments."

Statistic 4

"A study showed Bevacizumab improved a 6-month progression-free survival rate to 42.6% in new cases and gave a median overall survival of 9.2 months in recurrent Glioblastoma."

Statistic 5

"The use of D2C7-IT immunotoxin has shown a significant reduction in tumor volume by as much as 97.3% in preclinical trials."

Statistic 6

"A clinical trial of DCVax-L reported 67% of patients were alive at 3 years."

Statistic 7

"In the phase II trial of ABT-414, the median overall survival was 8.8 months."

Statistic 8

"In a trial involving Onalespib, 5 out of 17 patients achieved stabilization of their disease."

Statistic 9

"In a clinical trial, 80% of the patients using the Toca 511 & Toca FC regimen were alive at 1 year."

Statistic 10

"In a Phase 1b/2a study, Depatux-M in combination with TMZ and radiation improved the median overall survival in newly diagnosed glioblastoma patients to 17.8 months."

Statistic 11

"A phase 2 trial of Pembrolizumab in the recurrent glioblastoma set, the 6-month progression-free survival rate was 26%."

Statistic 12

"In the IMagyn050 study of Avastin (bevacizumab) in patients with newly diagnosed glioblastoma, the median progression-free survival was 10.6 months."

Statistic 13

"The IL13-PE38QQR phase III trial suggested a 50% increase in 3-month progression-free survival rate."

Statistic 14

"In a phase II trial of SurVaxM, over 95.7% of enrolled patients were alive at six months."

Statistic 15

"In the EF-14 trial, adding Tumor Treating Fields to maintenance temozolomide chemotherapy led to a median overall survival of 20.9 months."

Statistic 16

"The phase 1b study results of Glioblastoma multiforme patients treated with Carboxyamidotriazole Orotate (CTO) showed a median overall survival of 13.6 months."

The statistics presented indicate significant progress in the treatment and management of Glioblastoma, a challenging and aggressive form of brain cancer. Various clinical trials have shown promising results in terms of improved survival rates, treatment response, and progression-free survival. From Optune to Pembrolizumab, Tumor Treating Fields, Bevacizumab, and other innovative treatments, the data suggest advancements in both overall survival and quality of life for patients with Glioblastoma. These findings underscore the importance of ongoing research and the potential for more effective treatment options in the future.

Jannik Lindner

Jannik is the Co-Founder of Gitnux and has been working in the digital space since 2016. He is specialized in content and tech.

Can You Trust Our Report?

The statistics are checked by us and then entered into the database. Our market data reports have been linked to by some of the largest publishers and companies on the Internet.

Learn more about our process here.